{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-001448","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.660032+00:00","generated_at":"2026-06-27T03:54:26.515393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celldex Q4 net loss $20.1M; CDX-0159 Phase 2 urticaria studies to start Q2 2022","bullets":["Net loss of $20.1M ($0.43 diluted EPS) for Q4 2021; full year net loss $70.5M ($1.64 EPS).","Cash and marketable securities $408.3M as of Dec 31, 2021; provides runway through 2025.","CDX-0159 Phase 1b CSU data expected July 2022; Phase 2 studies in CSU and CIndU to initiate Q2 2022.","Plans to expand CDX-0159 development into eosinophilic esophagitis (EoE) with Phase 2 trial in Q4 2022.","Subcutaneous formulation of CDX-0159 well tolerated; supports planned Phase 2 doses of 75mg, 150mg, 300mg."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-001448","json":"https://secwatch.observer/filing/0001171843-22-001448.json","markdown":"https://secwatch.observer/filing/0001171843-22-001448.md","text":"https://secwatch.observer/filing/0001171843-22-001448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184322001448/0001171843-22-001448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184322001448/f8k_022822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:54:26.515393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}